26 Dec, EOD - Indian

SENSEX 78472.48 (0.00)

Nifty 50 23750.2 (0.10)

Nifty Bank 51170.7 (-0.12)

Nifty IT 43664.25 (-0.01)

Nifty Midcap 100 57125.7 (0.12)

Nifty Next 50 69165.85 (0.45)

Nifty Pharma 22712.55 (0.68)

Nifty Smallcap 100 18728.65 (-0.02)

26 Dec, EOD - Global

NIKKEI 225 39568.06 (1.12)

HANG SENG 20098.29 (1.08)

S&P 6089.5 (-0.34)

Login/Signup
LOGIN HERE
Cancel

Glenmark Pharmaceuticals Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 532296 | NSE Symbol : GLENMARK | ISIN : INE935A01035 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
30-Oct-2024 14-Nov-2024 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2024. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2024. The said Board Meeting commenced at 02:00 p.m. and ended at 6.20 p.m. (As Per BSE Announcement Dated on: 14/11/2024)
31-Jul-2024 14-Aug-2024 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the First quarter ended June 30 2024. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the First Quarter ended 30th June, 2024 (As per BSE Announcement Dated on 14/08/2024)
10-Jul-2024 10-Jul-2024 Others Disclosure pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached for your records.
14-May-2024 24-May-2024 Accounts GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2024 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2024. Please find enclosed financial results for the quarter and year ended March 31, 2024 along with recommendation of dividend. (As Per BSE Announcement Dated on 24.05.2024)
30-Jan-2024 14-Feb-2024 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2023. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2023. The said meeting of the Board commenced at 2.00 p.m. and concluded at 06:20 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company (As Per BSE Announcement Dated on 14/02/2024)
31-Oct-2023 10-Nov-2023 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2023. Intimation for closure of trading window Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2023. The said Board Meeting commenced at 02:00 p.m. and ended at 06:40 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com. (As per BSE Announcement Dated on 10/11/2023)
05-Oct-2023 05-Oct-2023 Postal Ballot The Board of Directors of the Company at its meeting held today, October 05, 2023 have decided to seek the consent of the Members by way of special resolution through Postal Ballot Process for the following: 1. To consider and approve the Sale of Equity Shares of Glenmark Life Sciences Limited, a material subsidiary of the Company. The Board of Directors have appointed Mr. Surjan Singh Rauthan, Practicing Company Secretary, who has given his consent to act as the Scrutinizer, for conducting Postal Ballot process in fair and transparent manner. The meeting commenced at 05:00 p.m. IST and concluded at 05:29 p.m. IST.
21-Sep-2023 21-Sep-2023 Others Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
31-Jul-2023 11-Aug-2023 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the First quarter ended June 30 2023. Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 2023 Re-appointment of Ms. Sona Saira Ramasastry (DIN 08398547) as Non-Executive Independent Director (As Per BSE Announcement Dated on 11.08.2023)
03-May-2023 19-May-2023 Accounts GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2023 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2023 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2023. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31 2023 to May 21 2023 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31 2023. The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on May 19, 2023, which commenced at 02.00 p.m. and concluded at 06.40 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2023. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com 2. Recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2022-23 subject to the approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on 19/05/2023)
13-Jan-2023 10-Feb-2023 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve We have to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 a meeting of the Board of Directors will be held on Friday February 10 2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2022. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31 2022 to February 12 2023 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2022. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2022. The said meeting of the Board commenced at 2.00 p.m. and concluded at 7.25 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company. Based on the recommendation of the Nomination and Remuneration Committee, the Board of the Company at its Meeting held today has approved the appointment of Mrs. Vijayalakshmi Rajaram Iyer (DIN: 05242960) as an Additional Director designated as Non-Executive - Independent, not liable to retire by rotation, effective today i.e. February 10, 2023. (As Per BSE Announcement dated on 10.02.2023)
02-Nov-2022 11-Nov-2022 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve We have to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 a meeting of the Board of Directors will be held on Friday November 11 2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2022. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30 2022 to November 13 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30 2022. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2022. The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.20 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com (As Per BSE Announcement dated on 11.11.2022)
29-Jul-2022 10-Aug-2022 Quarterly Results GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve We have to inform you that pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations 2015 a meeting of the Board of Directors will be held on Wednesday August 10 2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30 2022. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from June 30 2022 to August 12 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the First quarter ended June 30 2022. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2022. The said meeting of the Board commenced at 2.00 p.m. and concluded at 6.10 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release Investor Presentation and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company (As Per BSE Announcement dated on 10.08.2022)
18-May-2022 27-May-2022 Accounts GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2022 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2022. Further as per the 'Code of Conduct for Prevention of Insider Trading' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 31 2022 to May 29 2022 (both days inclusive) for the purpose of approval of Audited Financial Results for the Quarter and year ended March 31 2022. Audited Financial Results for the year ended March 31, 2022. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Management Discussion & Analysis, Press Release, Investor Presentation, Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com (As Per BSE Announcement Dated on 27.05.2022) Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2022, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2021- 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated 28.05.2022)
07-Apr-2022 07-Apr-2022 Change in Directors Pursuant to Regulation 30 of the SEBI LODR, Regulations 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee, Board at its meeting held today, has approved the following: a) Re-appointment of Mr. Glenn Saldanha (DIN- 00050607) as Chairman & Managing Director of the Company for a further period of 5 years with effect from 16th May, 2022; and b) Re-appointment of Mrs. Cherylann Pinto (DIN- 00111844) as an Executive Director - Corporate Services of the Company for a further period of 5 years with effect from 16th May, 2022
1 2